Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR00208 in Combination With Lenalidomide or Ibrutinib for CLL/SLL/PLL and RT
NCT02005289Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jan 2014
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), Richter's transformation (RT), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Jan 2014; status: completed.
02
Drugs
tafasitamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)prolymphocytic leukemia (PLL)Richter's transformation (RT)
Beyond the preview
Go deeper on NCT02005289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02005289.